A Review of Regulatory Settlements, Corporate Governance, Financial Performance, Executive Compensation, and Leadership Accountability Under CEO

A Review of Regulatory Settlements, Corporate Governance, Financial Performance, Executive Compensation, and Leadership Accountability Under CEO Sarah London

Executive Summary

Centene Corporation has become one of the largest government-funded healthcare organizations in the United States, generating more than $150 billion in annual revenue while administering Medicaid, Medicare, Affordable Care Act Marketplace, TRICARE, and correctional healthcare programs across dozens of states.

Because the overwhelming majority of Centene's revenue originates from taxpayer-funded healthcare programs, the company operates under heightened public trust and regulatory expectations.

Over the past several years, Centene has experienced an extraordinary number of legal settlements, regulatory investigations, financial setbacks, organizational restructurings, shareholder lawsuits, and public controversies. While many of these matters began before Sarah London became Chief Executive Officer in March 2022, they continue to define the environment she now leads.

This report examines publicly available information regarding:

Medicaid pharmacy settlements approaching $1 billion
Federal cybersecurity enforcement actions
Financial reporting failures and withdrawn earnings guidance
Shareholder litigation
Executive compensation
Workforce reductions and outsourcing
Corporate governance concerns
Strategic acquisitions and divestitures
Public policy implications for taxpayers

The purpose of this report is not to establish wrongdoing where none has been proven. Rather, it evaluates whether recurring events indicate broader governance, oversight, or accountability concerns deserving additional public examination.

# Section 1

## Company Overview

Centene Corporation is among the nation's largest managed care organizations.

Its principal business consists of administering publicly funded healthcare through contracts with federal and state governments.

Major business lines include:

Medicaid
Medicare Advantage
Medicare Part D
Affordable Care Act Marketplace plans
TRICARE support services
Behavioral health management
Pharmacy benefit management
Specialty healthcare services

Because most revenues originate from public programs, taxpayers ultimately finance a significant portion of Centene's operations.

This creates a higher expectation for:

Financial transparency
Regulatory compliance
Accurate reporting
Effective stewardship of public funds
Ethical corporate governance

# Section 2

## Nearly One Billion Dollars in Medicaid Pharmacy Settlements

Perhaps no issue has affected Centene's public reputation more than the series of settlements involving allegations related to Medicaid pharmacy benefit management.

Beginning in 2021, state attorneys general and Medicaid agencies alleged that Centene subsidiaries improperly reported prescription dr-g costs or retained pharmacy-related savings that should have been returned to Medicaid programs.

States reaching settlements include:

California
Texas
Ohio
Florida
Mississippi
Washington
Arkansas
Kansas
Louisiana
New Hampshire
New Mexico
and numerous others.

Collectively, publicly reported settlements have approached approximately one billion dollars.

Although Centene generally denied wrongdoing and resolved these matters without admitting liability, the repeated nature of the settlements raises legitimate policy questions regarding:

Internal financial controls
Pharmacy oversight
Compliance monitoring
Executive supervision
Board governance

A single settlement may represent an isolated disagreement.

Repeated settlements involving numerous states warrant broader public scrutiny.

# Section 3

## The Florida Settlement and Subsequent Political Controversy

Centene's Florida Medicaid settlement became significantly more controversial after approximately $10 million of settlement proceeds were directed to the Hope Florida Foundation.

Subsequent reporting found that funds distributed through the nonprofit later reached organizations involved in political advocacy.

The controversy primarily concerns decisions made by state officials rather than allegations that Centene directed political activity.

Nevertheless, the settlement became part of a broader debate regarding:

Transparency
Public accountability
Government contracting
Use of Medicaid settlement proceeds

Given Centene's continued participation in Florida's Medicaid program, the issue has generated substantial legislative attention.

# Section 4

## Federal Cybersecurity Settlement

In February 2025, Centene and Health Net Federal Services agreed to pay more than $11 million to resolve allegations under the False Claims Act involving cybersecurity compliance on the TRICARE contract.

According to the Department of Justice, the government alleged deficiencies including:

Untimely vulnerability remediation
Failure to fully implement required security controls
Inaccurate compliance certifications

Although these allegations primarily involved conduct predating Sarah London's appointment as CEO, the settlement illustrates ongoing regulatory exposure affecting the organization.

# Section 5

## Financial Forecasting Failure

One of the defining events of Sarah London's leadership occurred during 2025 when Centene unexpectedly withdrew previously issued earnings guidance.

The company disclosed significant changes involving:

Marketplace member health risk
Medical expense projections
Risk adjustment revenue
Affordable Care Act enrollment assumptions

The resulting revision represented approximately a $1.8 billion impact.

Investors responded immediately.

Centene experienced one of the largest single-day declines in company history.

Billions of dollars in market value were erased.

The company later reported its first adjusted quarterly loss in more than a decade.

This event prompted serious questions regarding:

Financial forecasting
Executive oversight
Internal reporting systems
Actuarial assumptions
Board supervision

# Section 6

## Shareholder Litigation

Following the withdrawal of guidance, multiple shareholder lawsuits were filed against Centene and senior executives.

The complaints generally allege that investors received overly optimistic information regarding:

Financial outlook
Marketplace performance
Medical costs
Revenue expectations

These allegations remain pending.

No court has determined liability.

Nevertheless, the litigation reflects a significant loss of investor confidence.

# Section 7

## Executive Compensation

Sarah London's publicly disclosed compensation has remained approximately $20 million annually.

Supporters argue that executive compensation reflects the complexity of managing one of America's largest healthcare organizations.

Critics note that this compensation coincided with:

Stock price declines
Workforce reductions
Regulatory settlements
Financial forecasting failures
Organizational restructuring

The issue is not whether executive compensation is legally permissible.

The issue is whether executive pay appropriately reflects organizational performance and accountability.

# Section 8

## Workforce Reductions and Outsourcing

Centene has pursued substantial organizational restructuring.

Reported actions include:

Workforce reductions
Voluntary separation programs
Office consolidations
Divestitures
Increased automation
Expanded outsourcing

Reports also indicate that Centene entered into a technology agreement with Cognizant valued at more than $500 million and potentially approaching $1 billion.

The reported initiative emphasizes:

Artificial intelligence
Claims automation
Customer service modernization
Administrative efficiencies

Critics argue that simultaneous workforce reductions and increased outsourcing may negatively affect employee morale, institutional knowledge, and organizational stability.

# Section 9

## Leadership Accountability

Sarah London inherited many of Centene's legacy legal matters.

However, executive leadership ultimately bears responsibility for:

Organizational culture
Financial controls
Regulatory compliance
Strategic direction
Public accountability

To date, there is no public evidence that Sarah London personally engaged in fraud or criminal misconduct.

The primary questions concern executive judgment, governance, operational oversight, and corporate performance rather than personal wrongdoing.

# Preliminary Conclusions

Based upon publicly available information, several recurring themes emerge.

1. Repeated Regulatory Exposure

Numerous settlements across multiple states suggest systemic compliance challenges rather than isolated disputes.

2. Financial Governance Concerns

The 2025 withdrawal of earnings guidance represents one of the most significant operational failures in recent company history.

3. Increasing Public Accountability

Because Centene receives substantial taxpayer funding, operational failures have implications extending beyond shareholders to state governments, beneficiaries, and taxpayers.

4. Leadership Performance

Sarah London's tenure has coincided with significant restructuring, operational modernization, and continuing legal challenges. Whether these actions ultimately strengthen the organization remains an open question that will be judged by future financial performance, regulatory compliance, and restored investor confidence.

## Areas Warranting Additional Review

Future investigation could examine:

Board oversight of pharmacy benefit management practices.
Internal audit findings before major settlements.
Executive incentive compensation tied to quality, compliance, and financial performance.
The impact of outsourcing and artificial intelligence on claims accuracy and member services.
The adequacy of forecasting controls preceding the 2025 guidance withdrawal.
Trends in state regulatory actions, corrective action plans, and sanctions involving Centene subsidiaries.
Corporate governance practices compared with peer managed care organizations.

### Executive Summary